Last reviewed · How we verify

Low-dose CAR-T cells group

Guangzhou Women and Children's Medical Center · Phase 3 active Biologic

Low-dose CAR-T cells group is a CAR-T cell therapy Biologic drug developed by Guangzhou Women and Children's Medical Center. It is currently in Phase 3 development for Hematologic malignancies (specific indication not specified in available data).

Low-dose CAR-T cells are engineered T lymphocytes expressing chimeric antigen receptors at reduced cell doses to target and kill cancer cells while potentially reducing toxicity.

Low-dose CAR-T cells are engineered T lymphocytes expressing chimeric antigen receptors at reduced cell doses to target and kill cancer cells while potentially reducing toxicity. Used for Hematologic malignancies (specific indication not specified in available data).

At a glance

Generic nameLow-dose CAR-T cells group
SponsorGuangzhou Women and Children's Medical Center
Drug classCAR-T cell therapy
TargetTumor-associated antigens (specific target antigen not specified)
ModalityBiologic
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

CAR-T cell therapy involves genetically modifying a patient's own T cells to express synthetic receptors that recognize tumor-associated antigens. Low-dose formulations aim to maintain anti-tumor efficacy while decreasing the incidence and severity of cytokine release syndrome and neurotoxicity associated with standard-dose CAR-T therapy. This approach may improve the therapeutic window by balancing tumor control with tolerability.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Low-dose CAR-T cells group

What is Low-dose CAR-T cells group?

Low-dose CAR-T cells group is a CAR-T cell therapy drug developed by Guangzhou Women and Children's Medical Center, indicated for Hematologic malignancies (specific indication not specified in available data).

How does Low-dose CAR-T cells group work?

Low-dose CAR-T cells are engineered T lymphocytes expressing chimeric antigen receptors at reduced cell doses to target and kill cancer cells while potentially reducing toxicity.

What is Low-dose CAR-T cells group used for?

Low-dose CAR-T cells group is indicated for Hematologic malignancies (specific indication not specified in available data).

Who makes Low-dose CAR-T cells group?

Low-dose CAR-T cells group is developed by Guangzhou Women and Children's Medical Center (see full Guangzhou Women and Children's Medical Center pipeline at /company/guangzhou-women-and-children-s-medical-center).

What drug class is Low-dose CAR-T cells group in?

Low-dose CAR-T cells group belongs to the CAR-T cell therapy class. See all CAR-T cell therapy drugs at /class/car-t-cell-therapy.

What development phase is Low-dose CAR-T cells group in?

Low-dose CAR-T cells group is in Phase 3.

What are the side effects of Low-dose CAR-T cells group?

Common side effects of Low-dose CAR-T cells group include Cytokine release syndrome, Neurotoxicity, Cytopenias, Infections.

What does Low-dose CAR-T cells group target?

Low-dose CAR-T cells group targets Tumor-associated antigens (specific target antigen not specified) and is a CAR-T cell therapy.

Related